Simple Summary In addition to cancer-related factors, anti-cancer chemotherapy treatment
can drive life-threatening body wasting in a syndrome known as cachexia. Emerging …

Elucidation of the mitochondrial regulatory mechanisms for the understanding of muscle
bioenergetics and the role of mitochondria is a fundamental problem in cellular physiology …

Muscle weakness and wasting are defining features of cancer-induced cachexia.
Mitochondrial stress occurs before atrophy in certain muscles, but the possibility of …

Perfluorooctane sulfonate (PFOS), one kind of persistent organic pollutants, is associated
with insulin resistance (IR) in general population. However, the exact mechanism is still …

In Duchenne muscular dystrophy, a lack of dystrophin leads to extensive muscle weakness
and atrophy that is linked to cellular metabolic dysfunction and oxidative stress. This …

MYO19 interacts with mitochondria through a C‐terminal membrane association domain
(MyMOMA). Specific mechanisms for localization of MYO19 to mitochondria are poorly …

Two prominent frontline breast cancer (BC) chemotherapies commonly used in combination,
doxorubicin (DOX) and docetaxel (TAX), are associated with long-lasting cardiometabolic …

Background Paclitaxel is a chemotherapy used for the treatment of solid cancers. Patients
receiving paclitaxel report fatigue. Melatonin is anti-inflammatory, antioxidant, and …

Identification of the mitochondrial roles and regulatory mechanisms for the understanding of
muscle bioenergetics is a fundamental problem in physiology/pathophysiology. The three …

Doxorubicin (Dox) is a commonly used chemotherapeutic that can adversely affect skeletal
muscle, including causing muscle atrophy. Dox is known to induce an event known as …